Page 45 - Merck Sharp News Today

The Catheter Related Bloodstream Infection (CRBSI) Market is anticipated to reach US$ 44.67 billion in 2023 and US$ 80 billion by 2023 to 2033 at a CAGR of 6%. The rise in the market for catheter-related bloodstream infections can be linked to the rise in the number of persons who experience urine infections. The ma...

SAN FRANCISCO — Pembrolizumab monotherapy exhibited antitumor activity among certain patients with high-risk non-muscle-invasive bladder cancer, according to results of a single-arm phase 2 study.The findings — presented at ASCO Genitourinary Cancers Symposium — highlighted the agent’s potential benefit among patients with papillary tumors without carcinoma in situ who did

One of the first oral PCSK9 inhibitors tested in trials significantly reduced LDL cholesterol levels in patients with high cholesterol.

Pembrolizumab was active in patients with high-risk, papillary NMIBC who did not undergo radical cystectomy and did not respond to BCG.

Adding pembrolizumab to pemetrexed-platinum chemotherapy improved 5-year outcomes in previously untreated, metastatic, EGFR/ALK-wild-type NSCLC.

Adding pembrolizumab to frontline chemotherapy improves outcomes in patients with HER2-, advanced gastric or GEJ cancers, a phase 3 trial suggests.

Significant improvements in six-minute walking distance were reported in the STELLAR Phase III Trial whose findings were unveiled during a Featured Clinical Research session on the final day of the March 4-6 American College of Cardiology Scientific Session, ACC23 Together with WCC. Researchers added a novel first-in-class medication in combination with background therapy in patients with pulmonary arterial hypertension (PAH), a severe, progressive condition that affects the heart and lungs.

Patients with pulmonary arterial hypertension (PAH), a severe, progressive condition that affects the heart and lungs, who were treated with the novel first-in-class medication sotatercept on top of existing therapy experienced significant improvements in walking distance via a six-minute walking test—the study's primary endpoint and a validated surrogate for functional improvement and reduced symptom burden.

MK-0616, an experimental oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, met its primary endpoint and substantially reduced levels of low-density lipoprotein (LDL) cholesterol in people with high cholesterol and/or heart disease related to clogged arteries, in a study being presented at the American College of Cardiology's Annual Scientific Session Together With the World Congress of Cardiology.

Patients with advanced melanoma have better event-free survival if pembrolizumab is given both before and after surgery; the findings tally with the mechanism of action of the drug, say researchers.